DIANTHUS THERAPEUTICS INC (DNTH)
Health Care · Biopharmaceutical - clinical-stage drug development · NASDAQ
A clinical-stage therapeutics company developing novel small-molecule drug candidates for undisclosed therapeutic indications.
What DIANTHUS THERAPEUTICS INC does
Dianthus Therapeutics is a biopharmaceutical company focused on the research, development, and potential commercialization of novel therapeutic drug candidates. The company is advancing two primary product candidates: claseprubart and DNTH212, through preclinical and clinical development activities. The company's operations are centered on managing its intellectual property rights, executing clinical trials, and pursuing regulatory approvals from the FDA and other authorities for its pipeline products.
Themes: ["clinical-stage drug development"]
Fundamentals
- Price$100.03 as of 2026-07-09 close
- Market cap$5.5B as of 2026-07-10
- 1-year return+374.3% as of 2026-07-09 close
- Net margin-12998.5% as of 2026-07-10
- ROE-27.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-79.5% as of 2026-07-10
- Beta1.76 as of 2026-07-10
Key risks (from latest filing)
["Reliance on successful advancement of claseprubart and DNTH212 through clinical trials and FDA approval; failure to replicate early-stage positive results in later-stage trials could delay or prevent commercialization"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.